ReviewPharmaceuticals (Basel, Switzerland)2021
Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 37 citations in OpenAlex.
- Exploring Cannabinoid Effects Using Zebrafish (International journal of molecular sciences · 2025Review
- Review
- Binding Affinity of Synthetic Cannabinoids to Human Serum Albumin: Site Characterization and Interaction Insights.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Humanized CB1R Yeast Biosensor Enables Facile Screening of Cannabinoid Compounds.International journal of molecular sciences · 2024Article
- Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances.Forensic toxicology · 2023Review
- No Boundaries for Toxicology in Clinical Medicine: One Health, One Society and One Planet for All of Us.Journal of clinical medicine · 2023Article
- Interpol Review of Drug Analysis 2019-2022.Forensic science international. Synergy · 2023Review
- Characterisation of AMB-FUBINACA metabolism and CBForensic toxicology · 2023Article
- Article
- Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.Drug testing and analysis · 2022Article
- In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats.Communications biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.